228 related articles for article (PubMed ID: 32004711)
1. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
[TBL] [Abstract][Full Text] [Related]
2. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
[TBL] [Abstract][Full Text] [Related]
3. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
5. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
8. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
[TBL] [Abstract][Full Text] [Related]
9. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
[TBL] [Abstract][Full Text] [Related]
10. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
11. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
Paik W; Kim HS; Choi CG; Kim SJ
Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
[TBL] [Abstract][Full Text] [Related]
12. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
14. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
[TBL] [Abstract][Full Text] [Related]
16. Radiomics in peritumoral non-enhancing regions: fractional anisotropy and cerebral blood volume improve prediction of local progression and overall survival in patients with glioblastoma.
Kim JY; Yoon MJ; Park JE; Choi EJ; Lee J; Kim HS
Neuroradiology; 2019 Nov; 61(11):1261-1272. PubMed ID: 31289886
[TBL] [Abstract][Full Text] [Related]
17. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
18. A comparison of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast MRI with and without contrast agent leakage correction in paediatric brain tumours.
Novak J; Withey SB; Lateef S; MacPherson L; Pinkey B; Peet AC
Br J Radiol; 2019 Feb; 92(1094):20170872. PubMed ID: 30358415
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
